Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer's disease

• Published in: Neuropharmacology 2023-03, Vol.226, p.109371-109371, Article 109371
• Main Authors: Ribeiro, Deidiane Elisa, Petiz, Lyvia Lintzmaier, Glaser, Talita, Oliveira-Giacomelli, Ágatha, Andrejew, Roberta, Saab, Fernando de Azevedo Ribeiro, Milanis, Milena da Silva, Campos, Henrique Correia, Sampaio, Vanessa Fernandes Arnaud, La Banca, Sophia, Longo, Beatriz Monteiro, Lameu, Claudiana, Tang, Yong, Resende, Rodrigo Ribeiro, Ferreira, Sergio T., Ulrich, Henning
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - psychology; Alzheimer's disease; Behavioral Symptoms - etiology; Cognitive Dysfunction; Depressive disorders; Humans; Neuropsychological Tests; Purinergic signaling; Sleep disorders; Sleep Wake Disorders - etiology
• ISSN: 0028-3908; 1873-7064
• DOI: 10.1016/j.neuropharm.2022.109371

About 10 million new cases of dementia develop worldwide each year, of which up to 70% are attributable to Alzheimer's disease (AD). In addition to the widely known symptoms of memory loss and cognitive impairment, AD patients frequently develop non-cognitive symptoms, referred to as behavioral and psychological symptoms of dementia (BPSDs). Sleep disorders are often associated with AD, but mood alterations, notably depression and apathy, comprise the most frequent class of BPSDs. BPSDs negatively affect the lives of AD patients and their caregivers, and have a significant impact on public health systems and the economy. Because treatments currently available for AD are not disease-modifying and mainly aim to ameliorate some of the cognitive symptoms, elucidating the mechanisms underlying mood alterations and other BPSDs in AD may reveal novel avenues for progress in AD therapy. Purinergic signaling is implicated in the pathophysiology of several central nervous system (CNS) disorders, such as AD, depression and sleep disorders. Here, we review recent findings indicating that purinergic receptors, mainly the A1, A2A, and P2X7 subtypes, are associated with the development/progression of AD. Current evidence suggests that targeting purinergic signaling may represent a promising therapeutic approach in AD and related conditions. This article is part of the Special Issue on “Purinergic Signaling: 50 years”. [Display omitted] •Mood and sleep disorders are frequent comorbidities in Alzheimer's disease.•Purinergic signaling is implicated in Alzheimer's disease, depression and sleep disorders.•A1 receptor stimulation and A2A or P2X7 receptor inhibition are neuroprotective.•Purinergic signaling may comprise a therapeutic target in Alzheimer's disease and comorbidities.